Document Detail


Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
MedLine Citation:
PMID:  19604443     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Imbalance of haemostasis in patients with rheumatoid arthritis (RA) contributes to future risk of cardiovascular diseases (CVD). Prothrombotic molecules, e.g. fibrinogen, D-dimer, and tPA are elevated in plasma of RA patients, being associated to CVD. There is no imformation about the influence of biological drugs, e.g. anti-CD20 and tumor necrosis factor (TNF) antibodies on these prothrombotic molecules. OBJECTIVE: To assess whether anti-TNF and anti-CD20 therapies modify the profiles of cardiovascular risk factors in patients with RA. METHODS: The expression of prothrombotic molecules in plasma was investigated in 10 RA patients before and after treatment with TNF-alpha antibodies and in another 12 RA patients before and after anti-CD20 treatment. RESULTS: Both anti-TNF and anti-CD20 infusions gave rise to clear clinical improvement. However, only anti-CD20 infusion significantly (p=0.05) reduced concentration of fibrinogen (p=0.05), D-dimer (p<0.001), as well as tPA levels (p<0.01). In contrast, in TNF antibody treated patients only tPA levels were significantly decreased following the treatment (p<0.05). CONCLUSIONS: Infusion of CD20 antibodies to the patients with active RA led to a clearly reduced plasma levels of predictors of CVD indicating that this treatment, apart from its anti-inflammatory properties, may reduce the risk for future CVD in RA.
Authors:
T Jin; M Bokarewa; S Amu; A Tarkowski
Related Documents :
23529023 - Clinical and imaging characteristics of dementia in multiple system atrophy.
12109923 - Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and...
20697253 - Chronic gastritis in the setting of autoimmune pancreatitis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  27     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2009 May-Jun
Date Detail:
Created Date:  2009-07-16     Completed Date:  2009-10-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  491-4     Citation Subset:  IM    
Affiliation:
Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, S-413 46 Göteborg, Sweden. tao.jin@rheuma.gu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / blood*,  drug therapy*
C-Reactive Protein / metabolism
Cardiovascular Diseases
Dose-Response Relationship, Drug
Female
Fibrin Fibrinogen Degradation Products / metabolism*
Fibrinogen / metabolism*
Humans
Male
Middle Aged
Plasminogen Activator Inhibitor 1 / blood*
Risk Factors
Tissue Plasminogen Activator / blood*
Tumor Necrosis Factor-alpha / antagonists & inhibitors,  immunology
Chemical
Reg. No./Substance:
0/Antibodies; 0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Antirheumatic Agents; 0/Fibrin Fibrinogen Degradation Products; 0/Plasminogen Activator Inhibitor 1; 0/Tumor Necrosis Factor-alpha; 0/fibrin fragment D; 0/infliximab; 0/rituximab; 9001-32-5/Fibrinogen; 9007-41-4/C-Reactive Protein; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decreased RAGE expression in peripheral blood mononuclear cells of patients with rheumatoid arthriti...
Next Document:  Absence of GDF5 does not interfere with LPS Toll-like receptor signaling.